PERSPECTA

News from every angle

← Back to headlines

Compass Therapeutics Stock Plunges After Drug Fails to Meet Endpoint

Compass Therapeutics' stock fell sharply after its drug, tovecimig, failed to meet its overall survival endpoint in a clinical trial.

27 Apr, 19:53 — 27 Apr, 19:53
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed4h ago

Compass Therapeutics plunges on tovecimig missing overall survival endpoint

Read full article →

Related Stories

'Astronauts back on Earth': Artemis II crew splashes down after record-breaking moon flyby – video

just now

Rare Plant Species Discovered in Bicol Natural Park, Philippines

just now

UP Institute Warns of Limits in Monterrazas Flood Study

47m ago

QuickCheck: Vestigial Third Eye in Humans

47m ago